Understanding Chronic Kidney Disease

Chronic kidney disease (CKD) is a silent epidemic affecting approximately 37 million Americans, or about 15 percent of the adult population. Many people do not know they have it until the disease is advanced, because early CKD rarely causes symptoms. The kidneys gradually lose their ability to filter waste and excess fluid from the blood, eventually progressing to end-stage kidney disease requiring dialysis or transplant.

CKD is classified in five stages based on the estimated glomerular filtration rate (eGFR), which measures how well the kidneys filter. Stages 1 and 2 represent mild damage with normal or near-normal filtration. Stage 3 (eGFR 30-59) is moderate CKD. Stages 4 and 5 represent severe CKD and kidney failure. Albuminuria (protein in the urine) is also a critical marker that indicates kidney damage and predicts progression. understanding CKD stages

The two leading causes of CKD are type 2 diabetes (responsible for roughly 44 percent of cases) and hypertension (responsible for about 29 percent). Obesity independently contributes to CKD through hyperfiltration, inflammation, and direct damage to the glomerular structures. These overlapping risk factors make metabolic medications a natural area of investigation for kidney protection.

What the Research Shows

The FLOW Trial: Definitive Kidney Evidence

The FLOW trial (Evaluate Renal Function with Semaglutide Once Weekly), published by Perkovic et al. in the New England Journal of Medicine in 2024, was the first dedicated kidney outcomes trial for any GLP-1 receptor agonist. It enrolled 3,533 patients with type 2 diabetes and CKD (eGFR 25 to 75 mL/min/1.73m2 with a urine albumin-to-creatinine ratio of 100 to 5,000).

Participants received semaglutide 1 mg weekly or placebo. The primary endpoint was the composite of sustained 50 percent decline in eGFR, end-stage kidney disease, renal death, or cardiovascular death. The trial was stopped early after a pre-specified interim analysis showed overwhelming efficacy.

Results showed a 24 percent reduction in the primary kidney composite endpoint (HR 0.76, 95% CI 0.66-0.88). Breaking down the components: sustained eGFR decline was reduced by 22 percent, end-stage kidney disease was reduced by 26 percent, and cardiovascular death was reduced by 29 percent. All-cause mortality was reduced by 20 percent.

eGFR Slope Analysis

The FLOW trial also tracked the rate of kidney function decline over time (the eGFR slope). Semaglutide slowed the annual rate of eGFR decline by approximately 1.16 mL/min/1.73m2 per year compared to placebo. While this may seem small in absolute terms, over 5 to 10 years it translates to years of additional kidney function and a significant delay in the need for dialysis.

Albuminuria Reduction

Semaglutide reduced the urinary albumin-to-creatinine ratio (UACR) by approximately 24 percent compared to placebo at 2 years. Since albuminuria is both a marker and a mediator of kidney damage, reducing it is considered a therapeutic target in its own right.

Earlier Evidence from SUSTAIN-6 and SELECT

Kidney secondary endpoints in SUSTAIN-6 had already hinted at renal benefit, with semaglutide reducing new or worsening nephropathy by 36 percent compared to placebo. The SELECT trial, in patients without diabetes, showed preserved eGFR and reduced albuminuria development in the semaglutide group.

How Semaglutide May Help

Semaglutide appears to protect the kidneys through multiple interconnected mechanisms. how GLP-1 medications protect kidneys

Reduced glomerular hyperfiltration: In obesity and early diabetic kidney disease, the kidneys filter at abnormally high rates (hyperfiltration), which damages the delicate glomerular structures over time. Weight loss and improved metabolic control reduce this hyperfiltration, allowing the kidneys to work at a more sustainable pace.

Blood pressure reduction: Hypertension is a primary driver of CKD progression. Semaglutide's 3 to 7 mmHg systolic blood pressure reduction provides incremental kidney protection on top of existing antihypertensive therapy.

Albuminuria reduction: The 24 percent reduction in UACR suggests that semaglutide reduces glomerular permeability, protecting the kidney's filtration barrier. The exact mechanism may involve reduced intraglomerular pressure, improved endothelial function, or anti-inflammatory effects on the glomerulus.

Anti-inflammatory and anti-fibrotic effects: CKD progression is driven in part by tubular inflammation and interstitial fibrosis. GLP-1 receptors are expressed in the kidney, and preclinical studies by Muskiet et al. in Diabetes showed that GLP-1 RA treatment reduced kidney inflammation markers and slowed fibrosis in diabetic animal models.

Improved glycemic control: Sustained hyperglycemia directly damages the kidney through AGE formation, oxidative stress, and PKC pathway activation. Semaglutide's HbA1c reduction of 1.0 to 1.8 percent helps mitigate these glucose-mediated injury pathways.

Important Safety Information

As of early 2026, semaglutide has received FDA approval for a CKD-related indication based on the FLOW trial results. This marks a significant expansion beyond its diabetes and weight management approvals.

In patients with CKD, special safety considerations apply. GI side effects (nausea, vomiting, diarrhea) can cause dehydration, which is particularly dangerous for patients with compromised kidney function. Dehydration can precipitate acute kidney injury (AKI) in CKD patients. Adequate fluid intake should be emphasized, especially during dose titration.

Patients on ACE inhibitors or ARBs (standard kidney-protective medications) should be monitored closely, as dehydration combined with RAAS blockade can worsen kidney function acutely. GLP-1 medications and kidney safety

Semaglutide carries a boxed warning about thyroid C-cell tumors and is contraindicated in patients with medullary thyroid carcinoma or MEN2.

Who Might Benefit

Based on the FLOW trial, semaglutide for CKD is most relevant for:

• Adults with type 2 diabetes and CKD stages 2 to 4 (eGFR 25 to 75) with significant albuminuria
• Patients already on maximum-tolerated RAAS blockade (ACE inhibitor or ARB) who need additional kidney protection
• Diabetic CKD patients at high cardiovascular risk, given the parallel cardiovascular death reduction seen in FLOW
• People with early CKD and obesity who could benefit from weight loss to reduce hyperfiltration

The FLOW trial enrolled patients with eGFR as low as 25, demonstrating safety and efficacy in moderate to severe CKD. However, semaglutide has not been studied in patients on dialysis or with eGFR below 25.

How to Talk to Your Doctor

If you have type 2 diabetes and CKD, the FLOW trial provides strong grounds for discussing semaglutide with your nephrologist or primary care doctor:

• Reference the FLOW trial by name and its 24 percent reduction in kidney disease progression
• Bring your most recent labs (eGFR, UACR, HbA1c) to the conversation
• Ask whether adding semaglutide to your RAAS blocker could provide additional kidney protection
• Discuss a hydration plan and monitoring schedule to mitigate dehydration risk during GI side effects

If your nephrologist is not yet prescribing GLP-1 agonists, consider asking for a referral to an endocrinologist who can coordinate the prescription. finding a GLP-1 prescriber

Frequently Asked Questions

Can semaglutide reverse kidney disease?

Semaglutide does not reverse existing kidney damage, but it significantly slows the progression of CKD. In the FLOW trial, the rate of kidney function decline was substantially slower with semaglutide, potentially delaying dialysis by years in many patients.

Is semaglutide safe with low kidney function?

The FLOW trial enrolled patients with eGFR as low as 25 mL/min/1.73m2 and demonstrated safety in this population. Semaglutide does not require dose adjustment based on kidney function since it is not primarily cleared by the kidneys. However, close monitoring for dehydration and acute kidney injury is essential.

How does semaglutide compare to SGLT2 inhibitors for CKD?

SGLT2 inhibitors (dapagliflozin, empagliflozin) have established kidney protection in CKD, with the DAPA-CKD and EMPA-KIDNEY trials showing 30 to 39 percent reductions in kidney disease progression. Semaglutide's 24 percent reduction in FLOW is in a similar range. Some nephrologists are now considering using both classes together, though dedicated combination trials are still needed.

Taking the Next Step

The FLOW trial has established semaglutide as a genuine kidney-protective agent, adding to its already impressive cardiovascular and metabolic profile. For the millions of people with diabetic kidney disease, this represents one of the most important treatment advances in recent years.

At FormBlends, we help you understand the research that shapes your treatment options. Talk with your healthcare team about whether semaglutide should be part of your kidney protection strategy. GLP-1 medications overview